Business Wire

TOKYO--(BUSINESS WIRE)-- FPT Software signed a Memorandum of Understanding (MOU) with JAL Information Technology (JIT), a subsidiary of JAL Infotec - an aviation technology solutions and services provider under Japan Airlines. This partnership will see both sides collaborating on the development of IT systems for aviation and non-aviation sectors, as well as exchanging human resources to enhance technical capability and expand business horizons. Besides, the two... (continue reading...)

With this new business, Kirin aims to solve social issue of excessive salt intake.

• Spoons with a unique current waveform that enhances the salty and umami taste of low-sodium foods are now available online.
• Initial sales are limited to 200 units, but sales will continue after June.

TOKYO--(BUSINESS WIRE)-- Kirin Holdings Company, Limited (Kirin) will launch as a new business in the Health Science domain (Health Science business) a limited offering of 200... (continue reading...)

Company to Unveil Next-Generation In-Car Sensor Technology and Road Communications

KYOTO, Japan--(BUSINESS WIRE)-- Kyocera Corporation (President: Hideo Tanimoto) announced its participation in the Automotive Engineering Exposition 2024 in Pacifico Yokohama, Kanagawa Prefecture May 22-24 (booth #N32). Kyocera will showcase a compact FIR auto sensor that detects pedestrians and vehicles even in darkness or severe weather conditions, and an experiential demo of an... (continue reading...)

www.HokuetsuCorpGov.com

HONG KONG--(BUSINESS WIRE)-- Oasis Management Company Ltd. (“Oasis”) is the manager to funds that beneficially own approximately 18% of Japanese paper manufacturer Hokuetsu Corporation (3865 JT) (“Hokuetsu” or the “Company”). Oasis has adopted the Japan FSA’s “Principles of Responsible Institutional Investors” (a/k/a the Japan Stewardship Code) and in line with those principles, Oasis monitors and engages with its... (continue reading...)

Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE’s impact on COPD exacerbations in patients with a broad range of eosinophil levels

WILMINGTON, Del.--(BUSINESS WIRE)-- The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1... (continue reading...)